Pharmacyte Biotech Stock Return On Asset
| PMCB Stock | USD 2.22 0.10 4.72% |
PharmaCyte Biotech fundamentals help investors to digest information that contributes to PharmaCyte Biotech's financial success or failures. It also enables traders to predict the movement of PharmaCyte Stock. The fundamental analysis module provides a way to measure PharmaCyte Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PharmaCyte Biotech stock.
As of April 23, 2024, Return On Assets is expected to decline to -0.06. PharmaCyte | Return On Asset |
PharmaCyte Biotech Company Return On Asset Analysis
PharmaCyte Biotech's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current PharmaCyte Biotech Return On Asset | -0.0524 |
Most of PharmaCyte Biotech's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PharmaCyte Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
PharmaCyte Return On Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for PharmaCyte Biotech is extremely important. It helps to project a fair market value of PharmaCyte Stock properly, considering its historical fundamentals such as Return On Asset. Since PharmaCyte Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of PharmaCyte Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of PharmaCyte Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
PharmaCyte Total Assets
Total Assets |
|
Based on the latest financial disclosure, PharmaCyte Biotech has a Return On Asset of -0.0524. This is 99.4% lower than that of the Biotechnology sector and 99.78% lower than that of the Health Care industry. The return on asset for all United States stocks is 62.57% lower than that of the firm.
PharmaCyte Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PharmaCyte Biotech's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PharmaCyte Biotech could also be used in its relative valuation, which is a method of valuing PharmaCyte Biotech by comparing valuation metrics of similar companies.PharmaCyte Biotech is currently under evaluation in return on asset category among related companies.
PharmaCyte Biotech Current Valuation Drivers
We derive many important indicators used in calculating different scores of PharmaCyte Biotech from analyzing PharmaCyte Biotech's financial statements. These drivers represent accounts that assess PharmaCyte Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of PharmaCyte Biotech's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 34.3M | 39.7M | 36.2M | 56.9M | 51.2M | 27.8M | |
| Enterprise Value | 33.5M | 37.6M | (49.2M) | (11.1M) | (10.0M) | (9.5M) |
PharmaCyte Fundamentals
| Return On Equity | -0.0174 | ||||
| Return On Asset | -0.0524 | ||||
| Current Valuation | (20.46 M) | ||||
| Shares Outstanding | 8.45 M | ||||
| Shares Owned By Insiders | 8.11 % | ||||
| Shares Owned By Institutions | 15.05 % | ||||
| Number Of Shares Shorted | 45.73 K | ||||
| Price To Earning | 9.57 X | ||||
| Price To Book | 0.60 X | ||||
| EBITDA | (4.32 M) | ||||
| Net Income | (4.32 M) | ||||
| Cash And Equivalents | 82.23 M | ||||
| Cash Per Share | 3.96 X | ||||
| Total Debt | 3.34 K | ||||
| Current Ratio | 75.51 X | ||||
| Book Value Per Share | 3.68 X | ||||
| Cash Flow From Operations | (3.79 M) | ||||
| Short Ratio | 0.98 X | ||||
| Earnings Per Share | (1.48) X | ||||
| Beta | -0.16 | ||||
| Market Capitalization | 17.92 M | ||||
| Total Asset | 73.28 M | ||||
| Retained Earnings | (115.96 M) | ||||
| Working Capital | 67.56 M | ||||
| Current Asset | 1.6 M | ||||
| Current Liabilities | 449 K | ||||
| Net Asset | 73.28 M |
About PharmaCyte Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PharmaCyte Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PharmaCyte Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PharmaCyte Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as PharmaCyte Biotech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out PharmaCyte Biotech Piotroski F Score and PharmaCyte Biotech Altman Z Score analysis. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.Note that the PharmaCyte Biotech information on this page should be used as a complementary analysis to other PharmaCyte Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Complementary Tools for PharmaCyte Stock analysis
When running PharmaCyte Biotech's price analysis, check to measure PharmaCyte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PharmaCyte Biotech is operating at the current time. Most of PharmaCyte Biotech's value examination focuses on studying past and present price action to predict the probability of PharmaCyte Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PharmaCyte Biotech's price. Additionally, you may evaluate how the addition of PharmaCyte Biotech to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |
Is PharmaCyte Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PharmaCyte Biotech. If investors know PharmaCyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PharmaCyte Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Return On Assets (0.05) | Return On Equity (0.02) |
The market value of PharmaCyte Biotech is measured differently than its book value, which is the value of PharmaCyte that is recorded on the company's balance sheet. Investors also form their own opinion of PharmaCyte Biotech's value that differs from its market value or its book value, called intrinsic value, which is PharmaCyte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PharmaCyte Biotech's market value can be influenced by many factors that don't directly affect PharmaCyte Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PharmaCyte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if PharmaCyte Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PharmaCyte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.